Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.44 USD
Change Today -0.0299 / -2.03%
Volume 67.3K
STXS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

stereotaxis inc (STXS) Snapshot

Open
$1.44
Previous Close
$1.47
Day High
$1.51
Day Low
$1.42
52 Week High
09/4/14 - $3.61
52 Week Low
12/16/14 - $1.32
Market Cap
30.2M
Average Volume 10 Days
58.5K
EPS TTM
$-0.21
Shares Outstanding
21.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEREOTAXIS INC (STXS)

Related News

No related news articles were found.

stereotaxis inc (STXS) Related Businessweek News

No Related Businessweek News Found

stereotaxis inc (STXS) Details

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and ablation devices designed to enhance interventional procedures. The company also offers Odyssey solution, which provides integrated real-time information solution to manage, control, record, and share procedures across networks worldwide. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters; and Pegasus coronary guidewire for cardiology procedures. Further, the company offers V-CAS catheter and V-CAS Deflect integrated catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. Stereotaxis, Inc. has strategic alliances with Siemens AG Medical Solutions; Philips Medical Systems; and Biosense Webster, Inc. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

133 Employees
Last Reported Date: 03/16/15
Founded in 1990

stereotaxis inc (STXS) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $662.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $423.8K
Vice President of Human Resources
Total Annual Compensation: $315.0K
Senior Vice President of Marketing & Business...
Total Annual Compensation: $435.0K
Compensation as of Fiscal Year 2014.

stereotaxis inc (STXS) Key Developments

Stereotaxis Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:30 PM

Stereotaxis Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:30 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: William C. Mills, Chairman of The Board, Chief Executive Officer and Chairman of Strategy & Technology Committee.

Stereotaxis, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Stereotaxis Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $9,531,026 against $8,354,670 a year ago. Operating loss was $1,414,278 against $2,228,992 a year ago. Net loss was $3,135,581 against $4,139,848 a year ago. Diluted net loss per common share was $0.15 against $0.21 a year ago.

Stereotaxis Inc. Elects Duane DeSisto to Board of Directors

Stereotaxis Inc. announced the election of medical device industry veteran Duane DeSisto to its Board of Directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation. His appointment increases the number of Stereotaxis board members to eight. Mr. DeSisto served as President and CEO of Insulet since 2001.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STXS:US $1.44 USD -0.0299

STXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.31 USD +0.17
Corindus Vascular Robotics Inc $3.63 USD -0.13
Hansen Medical Inc $0.85 USD +0.01
LeMaitre Vascular Inc $14.24 USD +0.84
Vascular Solutions Inc $37.23 USD +0.03
View Industry Companies
 

Industry Analysis

STXS

Industry Average

Valuation STXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEREOTAXIS INC, please visit www.stereotaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.